Cargando…

Pro-B-Type natriuretic peptide: a novel, specific biomarker for detection of left ventricular dysfunction in the general community

Detalles Bibliográficos
Autores principales:	Macheret, Fima, Heublein, Denise, Lahr, Brian, Costello-Boerrigter, Lisa, Boerrigter, Guido, McKie, Paul, Sandberg, Sharon, Rodeheffer, Richard, Cataliotti, Alessandro, Burnett, John C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3313357/ http://dx.doi.org/10.1186/1471-2210-9-S1-P44

Ejemplares similares

The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2011)

B-type natriuretic peptide single nucleotide polymorphism rs198389 and survival in the general community
por: Boerrigter, Guido, et al.
Publicado: (2009)

B-type natriuretic peptide single nucleotide polymorphism rs198389 is highly prevalent and impacts test characteristics of common assays
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2009)

Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines
por: Boerrigter, Guido, et al.
Publicado: (2011)

Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure
por: Boerrigter, Guido, et al.
Publicado: (2011)

C-Type natriuretic peptide: a potential urinary biomarker for renal remodeling and fibrosis during aging
por: Sangaralingham, Jeson S, et al.
Publicado: (2011)

Effects of long-term proBNP cardiac gene delivery in experimental hypertensive heart disease
por: Cataliotti, Alessandro, et al.
Publicado: (2011)

Cardiac Natriuretic Peptides: Contributors to Cardiac Cachexia or Possible Anti-obesity Agents or Both?
por: Costello-Boerrigter, Lisa C.
Publicado: (2012)

The degree of natriuretic peptide system activation in stable and high risk CHF characterized by increased cystatin C is not reflected in cGMP activation
por: Schirger, John A, et al.
Publicado: (2009)

M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics
por: McKie, Paul M, et al.
Publicado: (2013)

M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics
por: McKie, Paul M., et al.
Publicado: (2014)

Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure
por: Costello-Boerrigter, Lisa C, et al.
Publicado: (2011)

The Role of Natriuretic Peptides for the Diagnosis of Left Ventricular Dysfunction
por: Palazzuoli, Alberto, et al.
Publicado: (2013)

A Functional Genetic Variant (N521D) in Natriuretic Peptide Receptor 3 Is Associated with Diastolic Dysfunction: The Prevalence of Asymptomatic Ventricular Dysfunction Study
por: Pereira, Naveen L., et al.
Publicado: (2014)

Chronic natriuretic peptide protein therapeutics
por: Chen, Horng H, et al.
Publicado: (2013)

N-terminal pro-B-type natriuretic peptide and the diagnosis of left ventricular systolic dysfunction: what is the optimal cut-off?
por: Turley, A, et al.
Publicado: (2005)

MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results
por: Burnett, John C, et al.
Publicado: (2015)

Natriuretic Peptides in Assessment of Ventricular Dysfunction
por: Gorenjak, Maksimiljan
Publicado: (2003)

Ondernemen is … veranderen
por: Boerrigter, Michel
Publicado: (2021)

MRI-quantified left atrial epicardial adipose tissue predicts atrial fibrillation recurrence following catheter ablation
por: Chahine, Yaacoub, et al.
Publicado: (2022)

Natriuretic peptide vs. clinical information for diagnosis of left ventricular systolic dysfunction in primary care
por: Koschack, Janka, et al.
Publicado: (2008)

Natriuretic Peptide Levels and Stages of Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction
por: Dal Canto, Elisa, et al.
Publicado: (2023)

Mutagenicity of the peroxisome proliferators clofibrate, Wyeth 14,643 and di-2-ethylhexyl phthalate in the lacZ plasmid-based transgenic mouse mutation assay
por: Boerrigter, Michaël ETI
Publicado: (2004)

Relationship between Serum N-Terminal Pro-Brain Natriuretic Peptide Level and Left Ventricular Dysfunction and Extracellular Water in Continuous Ambulatory Peritoneal Dialysis Patients
por: Chung, Jong Hoon, et al.
Publicado: (2008)

Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides
por: Romano, Silvio, et al.
Publicado: (2010)

B-type natriuretic peptide for the prediction of left ventricular remodelling
por: Bauters, Christophe, et al.
Publicado: (2014)

Death is associated to the type of drug-eluting stent in patients with left ventricular dysfunction and elevated natriuretic peptide levels
por: Roth, Christian, et al.
Publicado: (2021)

Diagnostic accuracy of natriuretic peptide screening for left ventricular systolic dysfunction in the community: systematic review and meta‐analysis
por: Goyder, Clare R., et al.
Publicado: (2023)

N-terminal Pro-Brain Natriuretic Peptide Levels Predict Left Ventricular Systolic Function in Patients with Chronic Kidney Disease
por: Lee, Jung Eun, et al.
Publicado: (2009)

Elevated N-terminal pro-B-type natriuretic peptide levels and normal left ventricular systolic function: an echocardiographic study
por: Turley, A, et al.
Publicado: (2005)

Mutation of three amino acids in the disulfide-ring of a CNP based chimeric natriuretic peptide alters its vascular properties
por: Chen, Horng H, et al.
Publicado: (2009)

Correlation between N-Terminal Pro-Brain Natriuretic Peptide and Doppler Echocardiographic Parameters of Left Ventricular Filling Pressure in Atrial Fibrillation
por: Kim, Woo Shin, et al.
Publicado: (2011)

Addition of N-terminal Pro-B-type Natriuretic Peptide Levels to Electrocardiography Criteria for Detection of Left Ventricular Hypertrophy: The ARIRANG Study
por: Ahn, Min-Soo, et al.
Publicado: (2015)

An association between N-terminal pro-brain natriuretic protein level and risk of left ventricular hypertrophy in patients without heart failure
por: Huang, Lei, et al.
Publicado: (2020)

N-terminal pro-brain natriuretic peptide reflects both left ventricular diastolic dysfunction and myeloma-related renal insufficiency and robustly predicts mortality in patients with symptomatic multiple myeloma
por: Abe, Yoshiaki, et al.
Publicado: (2019)

Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with reduced NT-proANP, increased stroke and higher diastolic blood pressure
por: Pereira, Naveen L, et al.
Publicado: (2015)

Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up
por: Buglioni, Alessia, et al.
Publicado: (2015)

Right Atrial Pressure Affects the Interaction between Lung Mechanics and Right Ventricular Function in Spontaneously Breathing COPD Patients
por: Boerrigter, Bart, et al.
Publicado: (2012)

A New Chimeric Natriuretic Peptide, C(N)AA(C), for the Treatment of Left Ventricular Dysfunction after Myocardial Infarction
por: Zhang, Shu-Miao, et al.
Publicado: (2017)

Left ventricular dysfunction by conventional and tissue Doppler echocardiography in pediatric hemodialysis patients: relation with plasma brain natriuretic peptide levels
por: Mostafa, Fatma A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_opkel6nfi88bdh47oqfvep97c2